Bristol Myers Squibb (BMS) has secured a recommendation for priority review in China for its next‑generation molecular glue degrader, mezigdomide. The application seeks approval for mezigdomide combined with carfilzomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma (r/r MM) who have previously received lenalidomide and an anti‑CD38 antibody. This regulatory acceleration follows the presentation of pivotal Phase III data.

In the SUCCESSOR‑2 trial, the combination regimen demonstrated a statistically significant improvement, doubling median progression‑free survival (PFS) to 18.0 months compared to 8.3 months for the control group (HR=0.48). While the objective response rate (ORR) reached 80.2%, the regimen was associated with a higher incidence of grade 3–4 neutropoenia and infections, consistent with the drug's known safety profile.

PharmCube's NextBiopharm® database shows that BMS is also developing the candidate in two leukaemia indications. Click here to request a free trial for NextBiopharm®.